Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Incyte Corporation
Mural Oncology, Inc
Incyte Corporation
Universitaire Ziekenhuizen KU Leuven
NGM Biopharmaceuticals, Inc
Mayo Clinic
Astex Pharmaceuticals, Inc.
Eisai Inc.
pharmaand GmbH
Cedars-Sinai Medical Center
University of Virginia
Barbara Ann Karmanos Cancer Institute
University of Maryland, Baltimore
GOG Foundation
Dana-Farber Cancer Institute
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
Genentech, Inc.
Hoffmann-La Roche
Boehringer Ingelheim
Genentech, Inc.
Ohio State University Comprehensive Cancer Center
Hoffmann-La Roche
Henry M. Jackson Foundation for the Advancement of Military Medicine
Dana-Farber Cancer Institute
University of Southern California
M.D. Anderson Cancer Center
Eli Lilly and Company
Eli Lilly and Company